PHAXIAM Therapeutics S.A.
Paris Stock Exchange PHXM.PA
PHAXIAM Therapeutics S.A. Price to Sales Ratio (P/S) on January 14, 2025: 12.57
-
PHAXIAM Therapeutics S.A. 52-week high Price to Sales Ratio (P/S) is 31.32 on January 18, 2024, which is 149.17% above the current Price to Sales Ratio (P/S).
-
PHAXIAM Therapeutics S.A. 52-week low Price to Sales Ratio (P/S) is 11.19 on November 26, 2024, which is -10.94% below the current Price to Sales Ratio (P/S).
-
PHAXIAM Therapeutics S.A. average Price to Sales Ratio (P/S) for the last 52 weeks is 17.78.
| Date | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield | Free Cash Flow Yield |
|---|
| CEO | Mr. Thibaut du Fayet |
| IPO Date | May 7, 2013 |
| Location | France |
| Headquarters | 60 Avenue Rockefeller |
| Employees | 68 |
| Sector | Health Care |
| Industries | |
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email